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ABSTRACT
Objective: To explore if there is an increased cancer
risk associated with folic acid supplements given
orally.
Design: Systematic review and meta-analysis of
controlled studies of folic acid supplementation in
humans reporting cancer incidence and/or cancer
mortality. Studies on folic acid fortiﬁcation of foods
were not included.
Data sources: Cochrane Library, Medline, Embase
and Centre of Reviews and Dissemination, clinical trial
registries and hand-searching of key journals.
Results: From 4104 potential references, 19 studies
contributed data to our meta-analyses, including 12
randomised controlled trials (RCTs). Meta-analysis of
the 10 RCTs reporting overall cancer incidence
(N¼38233) gave an RR of developing cancer in
patients randomised to folic acid supplements of 1.07
(95% CI 1.00 to 1.14) compared to controls. Overall
cancer incidence was not reported in the seven
observational studies. Meta-analyses of six RCTs
reporting prostate cancer incidence showed an RR of
prostate cancer of 1.24 (95% CI 1.03 to 1.49) for the
men receiving folic acid compared to controls. No
signiﬁcant difference in cancer incidence was shown
between groups receiving folic acid and placebo/
control group, for any other cancer type. Total cancer
mortality was reported in six RCTs, and a meta-
analysis of these did not show any signiﬁcant
difference in cancer mortality in folic acid
supplemented groups compared to controls (RR 1.09,
95% CI 0.90 to 1.30). None of the observational
studies addressed mortality.
Conclusions: A meta-analysis of 10 RCTs showed
a borderline signiﬁcant increase in frequency of overall
cancer in the folic acid group compared to controls.
Overall cancer incidence was not reported in the seven
observational studies. Prostate cancer was the only
cancer type found to be increased after folic acid
supplementation (meta-analyses of six RCTs).
Prospective studies of cancer development in
populations where food is fortiﬁed with folic acid could
indicate whether fortiﬁcation similar to supplementation
moderately increases prostate cancer risk.
INTRODUCTION
Folic acid is a synthetic form of the essential
B vitamin folate, also named folacin, pter-
oylglutamic acid or vitamin B9. Folic acid is
in the human body converted to 5-methylte-
trahydrofolate, which also is the form of
folate found in dietary sources and is partic-
ularly abundant in vegetables, fruits and
grains. Folic acid is more stable than 5-
methyltetrahydrofolate, which is highly labile
and sensitive to oxidation. Folate is involved
in synthesis, repair and methylation of DNA,
and folate deﬁciency may lead to develop-
mental and degenerative conditions, such as
neural tube defects in developing embryos
and megaloblastic anaemia at any age. Folic
acid supplements are widely used to prevent
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ARTICLE SUMMARY
Article focus
- The present systematic review aims to explore if
there is an increased cancer risk associated with
folic acid supplements given orally.
Key messages
- Meta-analysis of 10 RCTs showed no beneﬁt but
a borderline signiﬁcant increase in incidence of
overall cancer in the folic acid group compared to
controls. Overall cancer incidence was not
reported in the seven observational studies.
When analysing site-speciﬁc cancers, prostate
cancer was the only cancer type where an
increase in risk was shown for folic acid
supplements.
- The current study does not show any evidence
for augmented cancer risk for fertile women who
are recommended folic acid periconceptionally in
order to reduce the risk of neural tube defects.
Strengths and limitations of this study
- This systematic review has been performed
with a thorough systematic search; and data
extraction and quality assessment have been
performed by at least two independent persons.
- The limited time of follow-up of most RCTs is
a limitation of our review because the time frame
for cancer development might exceed the follow-
up time in many RCTs.
- The highly selected population in which most
of the studies were conducted limits the
applicability to the general population and
women of childbearing age taking folic acid
periconceptionally.
Wien TN, Pike E, Wisløff T, et al. BMJ Open 2012;2:e000653. doi:10.1136/bmjopen-2011-000653 1
Open Access Researchand treat folate deﬁciency in groups at risk and also to
prevent adverse events associated with antifolate medi-
cation. In Norway, folic acid is among the 10 most sold
non-prescription drugs with 17.5 deﬁned daily doses per
1000 inhabitants/day.
1 Folic acid supplements may be
administered in various forms, such as tablets, mixtures
or intravenously. In addition, folic acid may be added to
foods as fortiﬁcation of, for example, grains and cereals.
The rationale for folic acid fortiﬁcation is prevention of
neural tube defects in developing embryos, and this
policy is advocated in several countries around the world
(such as in the USA and Canada) but not in Norway or
in the UK.
Fertile women are a large population group who are
recommended to take daily folic acid supplements,
starting the month before conception and lasting
throughout the ﬁrst trimester in order to prevent
possible neural tube defects in developing embryos.
Folate has also been widely used in patients with cardio-
vascular diseases because it lowers homocysteine, which
has been associated with increased risk of cardiovascular
events.
2 Recent data from meta-analyses, however, do not
show beneﬁt of folic acid supplementation on risk for
cardiovascular events.
3e5
Masking of vitamin B12 deﬁciency, with risk of irre-
versible nerve damage, is a well-known risk associated
with folic acid supplementation, especially in the older
population.
6 In general, however, folic acid supplemen-
tation has been considered safe. Foods containing folate
possibly decrease the risk of several cancers.
7 Folate is
involved in the synthesis of nucleotides and amino acids,
including methonine. In folic acid deﬁciency, the
primary intracellular methyl donor S-adenosylmethio-
nine is reduced, and synthesis, methylation and repair of
DNA are hampered and the resulting DNA instability
increases the risk of cancer development.
89Over the
past years, however, there have been rising concerns that
folic acid supplementation actually could increase the
risk of cancer, as animal and human studies have indi-
cated that high folate status might promote progression
of preneoplastic and undiagnosed neoplastic lesions.
10 11
A combined analysis from 2009
12 of two Norwegian
randomised controlled clinical trials,
13 14 with extended
post-trial follow-up, demonstrated an increased inci-
dence of cancer among patients taking folic acid for
homocysteine reduction as secondary prevention of
cardiovascular events.
The aim of the present systematic review was to
investigate whether folic acid supplement given orally
increases cancer incidence and cancer mortality in
humans. Risks associated with folic acid fortiﬁcation of
foods are beyond the scope of this review.
METHODS
We conducted a systematic review and several meta-
analyses of existing literature, following the methods
recommended in the PRISMA statement for reporting
systematic reviews and meta-analyses of studies that
evaluate healthcare interventions.
15 The methods of the
analyses and inclusion criteria were prespeciﬁed and
published in a protocol available at the web pages of the
Norwegian Knowledge Centre for the Health Services
and are available as online supplementary materials.
16
Eligibility criteria
We included systematic reviews, randomised controlled
trials (RCTs) and controlled observational studies
(caseecontrol and cohort studies) that assessed cancer
incidence and/or cancer mortality in any population
taking folic acid supplements $0.4 mg/day by oral route
for any indication. Folic acid could be taken with or
without other B vitamins and compared with any control.
We excluded studies where folic acid was given as part of
high-dose cytostatic regimen of cancer treatment. The
folic acid dose cut-off of $0.4 mg/day was set in order to
compare doses considered to have clinical relevance
across groups and studies.
Literature search
To identify all relevant published reports, we performed
a systematic literature search using medical subject
headings (MeSH) and free-text search terms for folate,
folic acid, cancer and neoplasm. We searched the
following electronic databases and web pages from
inception to present: Embase, Ovid Medline, Cochrane
Library, Centre for Reviews and Dissemination, NHS
evidence, Clinical evidence and ISI Web of Knowledge,
AHRQ, INAHTA, SBU, DACEHTA and FINOHTA. The
searches were conducted in March 2010, with supple-
mentary searches in Embase, Medline and Cochrane
Library on 6 May 2010. A ﬁlter for controlled studies was
used in order to reduce number of hits.
17 There were no
limits by language, and non-English papers with a rele-
vant English abstract were translated. The full search
strategy including the search terms for the various
databases is supplied at the web pages of the Norwegian
Knowledge Centre for the Health Services.
18 In addition,
we manually searched reference lists of review articles
and conducted limited updated non-systematic literature
searches in the same electronic databases up to 31
January 2011. For ongoing studies, we searched
WHO’s International clinical trials registry platform and
http://www.clinicaltrials.org, up to 10 February 2011.
Study authors were not contacted for additional
non-published data.
Data extraction and quality assessment
All citations identiﬁed by the search process were
screened by two reviewers independently (TNW and EP)
to determine if they met the eligibility criteria. Possible
relevant articles were retrieved in full text. To avoid
missing studies due to inconsistent vocabulary (folic
acid/folate), citations on dietary folate were also
retrieved in full text and assessed.
The quality of the included studies was assessed inde-
pendently by two reviewers (TNW and EP) using the
Cochrane Collaboration’s tool for Risk of Bias
2 Wien TN, Pike E, Wisløff T, et al. BMJ Open 2012;2:e000653. doi:10.1136/bmjopen-2011-000653
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19 for RCT’s and checklists for cohort and
caseecontrol studies.
20 The quality of the end points was
assessed by the same two reviewers using GRADE.
21
Study data were extracted using standardised tables by
three authors independently (TNW, EP and TW) and
were always extracted from the intention-to-treat popu-
lations. Any disagreements between the independent
assessments of the reviewers in literature selection, data
extraction and quality assessment were dissolved by
discussion or by a fourth reviewer (MK).
Statistical analyses
When feasible, we pooled data by meta-analyses with
Cochrane Collaboration software (RevMan5) and used
random-effects model calculating RRs with 95% CIs. For
trials with factorial design, we compared all groups that
received folic acid supplements $0.4 mg/day with
groups that did not. Analyses were conducted for both
crude data and adjusted data when possible. For RCT’s,
analyses of crude data are presented in this article, and
for observational data, adjusted analyses are presented.
In our analyses of adjusted data, we used the analyses
with the most explanatory variables if there were alter-
natives. These analyses were combined using generic
inverse variance in RevMan5. Sensitivity analyses were
predeﬁned for population characteristics such as sex,
age, body mass index, comorbidity and risk factors for
cancer such as smoking habits and characteristics of
intervention such as dose and time of exposure and time
to outcome assessment, that is, time of follow-up. As
individual patient data were not available, sensitivity
analyses were performed at trial level.
RESULTS
Literature search and characteristics of included studies
The literature search retrieved 4104 citations, and
additionally 31 citations were identiﬁed through manual
searches of reference lists and limited updated searches.
Fourteen articles from the literature search and seven
articles from the manual search, together covering 19
studies, were included (ﬁgure 1). The 19 included
studies represented 12 RCTs and seven observational
studies (six cohort studies and one caseecontrol study).
Details of the included RCTs are given in table 1 and of
the observational studies in table 2. All RCTs were
performed between 1994 and 2008, except for one study,
a 36-year follow-up of an RCT of folic acid given in
pregnancy, starting in 1966.
29 30 Baseline dietary data in
the observational studies were collected between 1984
and 1986 in the Nurses’ Health Study and Health
Professionals Follow-up Study
36 and up to 2000e2002 in
the VITamins And Lifestyle (VITAL) Cohort Study.
34 38
Seven RCTs were performed in populations with
cardiovascular disease or high-risk groups for cardiovas-
cular disease, three were in populations with a history of
colorectal adenoma, one in a population with atrophic
gastritis and one was performed in pregnant women.
Except for a cohort study in patients with ulcerative
colitis,
35 the populations in the observational studies
were not selected by any morbidity criteria but were
rather cohorts/caseecontrol studies selected by living
area or profession. All folic acid supplements were
administered as tablets, and in many of the RCTs given
in combinations with other interventions (table 1). Two
RCTs (NORVIT
13 and WENBIT
14 with a median of 40
and 38 months treatment, respectively) reported cancer
data of an additional 38 months post-trial observational
follow-up in a combined analysis published in 2009.
12 We
have in our meta-analysis used data from the combined
analysis stratiﬁed by trial but refer to the original publi-
cations
13 14 and count these studies (NORVIT and
WENBIT) as two RCTs. Two RCTs, HOST
24 and VISP,
25
did not report cancer data in the original publications,
but such data are provided in a recent meta-analysis from
which we have extracted cancer data.
3
When available, analyses were performed on adjusted
data in addition to crude data. These analyses gave the
same conclusions. For the RCTs, we present crude data
in text and ﬁgures (adjusted data are available at the web
pages of the Norwegian Knowledge Centre for the
Health Services
18).
Ongoing studies
Our search for ongoing and unpublished studies with
the search word ‘folic acid’ detected 1642 studies in
WHO’s International clinical trials registry platform and
245 trials in the http://ClinicalTrials.gov database. Only
two of these trials met our eligibility criteria including
cancer as predeﬁned outcome. One is an ongoing Dutch
study of vitamin B12 and folic acid supplementation for
Figure 1 Process of study selection. RCT, randomised
controlled trial.
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Cancer risk with folic acid supplementspreventing fractures in older people, with cancer as
secondary outcome.
39 The other is a prolonged post-trial
follow-up of the Norwegian studies WENBIT and
NORVITup to 2014,
40 for which we have data up to 2007
included in our analysis.
12
Excluded studies
Two hundred and twenty-ﬁve studies judged to be rele-
vant from screening of title/abstract were excluded after
full-text examination. List of excluded articles is avail-
able at the web pages of the Norwegian Knowledge
Centre for the Health Services.
18 Eighty-nine studies
were excluded due to missing or too low folic acid
supplement intervention, that is, the study did not
report data on folic acid supplements, only on dietary
folate (83 studies) or supplement dose was below
0.4 mg/day (six studies). In 95 studies, data were
incomplete by either no dose speciﬁcation on folic acid
supplementation or lacking cancer outcome data for
folic acid supplements (eg, risk was given for total folate
intake, not for folic acid per se). Additionally, 41 studies
were excluded due to other reasons, such as lack of
a control group or lacking data on cancer development
or mortality.
Methodological quality
Generally, the risk of bias in the included RCTs was low.
All the RCTs, except two, had low risk of bias, that is, they
had adequate sequence generation, allocation conceal-
ment, blinding and follow-up. The two remaining trials
had high
29 and unclear
31 risk of bias, respectively, mainly
due to inadequate or unclear reporting of sequence
generation and allocation concealment. These two trials
reported data on cancer mortality
29 and gastrointestinal
cancer,
31 not on overall cancer incidence, and thus do
not inﬂuence our overall estimate for this end point.
The quality of the evidence for the individual end points
was evaluated by use of GRADE. The outcomes from the
RCTs generally had high quality for cancer incidence
(high for total, colorectal, lung and prostate cancers;
and moderate for breast cancer). For cancer mortality,
the quality ranged from very low (breast), low (colorectal
and prostate) to moderate (total and lung cancer
mortality). The most common reason for lower quality
was the very low number of events. The quality of the
outcomes from the observational studies varied from low
to very low.
Cancer incidence
The pooled effect estimates from 10 RCTs
11 13 14 22e28
reporting total cancer incidence with folic acid supple-
mentation versus placebo were borderline signiﬁcant
with an RR of 1.07 (95% CI 1.00 to 1.14) (ﬁgure 2A). A
total of 3515 incident cancers were detected among
38233 participants. No heterogeneity across studies was
detected in the analysis (I
2¼0%). The funnel plot of this
analysis seemed symmetrical (ﬁgure 2B); hence, we have
no indication of publication bias based on this analysis.
Sensitivity analyses on trial level (table 3) showed
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Cancer risk with folic acid supplementsborderline increased risk of cancer development after
folic acid supplementation in the four studies including
>70% of men (RR 1.08, 95% CI 1.00 to 1.16) and in the
two studies including >30% of current smokers (RR
1.19, 95% CI 1.02 to 1.38). Sensitivity analysis on
comorbidity by separating studies in populations with
a history of adenoma from populations with cardiovas-
cular disease did not yield signiﬁcant increased risk for
developing cancer with folic acid supplementation in
either group. Distributions of age and body mass index
were very similar between the studies; thus, sensitivity
analysis on study level by those factors was not feasible.
Due to lacking data, we were not able to perform sensi-
tivity analyses on alcohol consumption, family history of
cancer or physical activity. Sensitivity analyses on folic
acid dosage showed increased risk in the four studies,
with a dose from 0.4 to 1 mg (RR 1.21, 95% CI 1.06 to
1.38) but not in those with folic acid doses above 1 mg.
Folic acid exposure time of <60 months did not yield
signiﬁcant risk differences between the groups. Longer
follow-up time, however, yielded borderline statistical
signiﬁcant increased cancer risk in the folic acid
supplemented group, with an RR of 1.09 (95% CI 1.00 to
1.18) in the six studies with >60 months of follow-up.
Folic acid supplements given in coadministration with
other B vitamins
12 24e28 did not show any signiﬁcant
difference between the groups. When administered
together with aspirin,
11 22 a borderline signiﬁcant
increased risk was shown in the folic acid groups
compared to the control groups (RR 1.43, 95% CI 1.00
to 2.03). Two of the RCTs
24 26 were done in the USA after
introduction of fortiﬁcation. Sensitivity analysis of those
two showed no signiﬁcant difference between the groups
(table 3).
Figure 2 Randomised controlled trials that compare folic acid supplements $0.4 g/day with placebo/control treatment with
respect to total cancer incidence. (A) Forest plot showing meta-analysis. (B) Funnel plot of effect estimates plotted against SEs
(on a reversed scale).
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Cancer risk with folic acid supplementsMeta-analysis of the seven observational studies
including all cancer types reported showed no difference
in cancer incidence between the group taking folic acid
supplements and abstainers (six cohort studies gave an
RR of 1.03, 95% CI 0.92 to 1.16; and one caseecontrol
study an RR of 0.96, 95% CI 0.54 to 1.68).
In RCTs reporting incident cancer type, prostate
cancer was the most common cancer type. In six
RCTs
13 14 23 27 28 41 with 25738 male participants, 349
incident cases of prostate cancer were found among
12867 participants in the folic acid groups and 283 cases
among 12871 participants in the control groups (RR
1.24, 95% CI 1.03 to 1.49) (ﬁgure 3). None of the
included observational studies reported on prostate
cancer. No statistically signiﬁcant augmented cancer
incidence risk was shown in the meta-analyses of inci-
dence of any other cancer types in RCTs or observational
studies. This included meta-analyses of RCTs of cancer
of the breast (RR 0.86, 95% CI 0.65 to 1.14, three
RCTs),
23 26 27 colon and rectum (RR 1.00, 95% CI 0.83 to
1.21, nine RCTs),
11 12 22 23 26e28 31 haematological
cancers (RR 1.16, 95% CI 0.76 to 1.78, four RCTs),
12 26 28
lung (RR 1.11, 95% CI 0.92 to 1.33, six RCTs)
12 23 26e28
and pancreas cancer (RR 1.50, 95% CI 0.42 to 5.31,
analysis of one RCT).
26 Correspondingly, none of the
observational studies showed any difference in cancer
incidence between the groups
32e38 as shown for breast
cancer (RR 1.02, 95% CI 0.75 to 1.39, two cohort
studies
32 34; and 0.96, 95% CI 0.54 to 1.68, one casee
control study
32), lung cancer (RR 0.99, 95% CI 0.79 to
1.24, one cohort study
38), pancreas cancer (RR 1.12,
95% CI 0.90 to 1.40, two cohort studies
36 37) and colon
and rectum cancer (RR 0.45, 95% CI 0.05 to 3.92, one
cohort study
35).
Cancer mortality
Total cancer mortality was reported in six RCTs,
13 14 26e29
with a total of 1134 cancer-related deaths among 32327
participants. With the exception of one study in pregnant
women,
29 30 all studies were performed in populations of
patients with cardiovascular disease. The pooled effect
estimate of all studies (ﬁgure 4A) showed no signiﬁcant
increase in cancer mortality in folic acid groups
compared to controls (RR 1.09, 95% CI 0.92 to 1.30).
Sensitivity analysis on trial level showed increased risk for
cancer mortality after folic acid supplementation in
studies with >30% of smokers (RR 1.38, 95% CI 1.10 to
1.72). This subgroup included 9299 participants from the
combined analysis of two Norwegian RCTs
12 (NORVIT
13
and WENBIT
14) after folic acid supplementation as
secondary prevention of cardiovascular events and from
a Scottish follow-up study
29 30 after folic acid supple-
mentation in pregnancy. Sensitivity analyses on sex, age,
comorbidity, dose folic acid or time of follow-up did not
yield signiﬁcant risk increase in any group.
Table 3 Sensitivity analyses on study level of population,
intervention and time to outcome assessment
Sensitivity analysis on study level RR (95% CI)
All 1.07 (1.00 to 1.14)
<70% men
11 22 23 25 26 1.05 (0.90 to 1.23)
>70% men
12 24 27 28 1.08 (1.00 to 1.16)
<30% smokers
11 23e28 1.05 (0.98 to 1.12)
>30% smokers
12 1.19 (1.02 to 1.38)
<15% smokers
23 26e28 1.04 (0.97 to 1.13)
>15% smokers
11 12 24 25 1.12 (0.93 to 1.35)
History of colorectal
adenoma
11 22 23
1.28 (0.95 to 1.72)
History of cardiovascular
disease
12 24e28
1.06 (0.99 to 1.13)
0.4e1 mg folic acid/day
11 12 22 23 1.21 (1.06 to 1.38)
>1 mg folic acid/day
24e28 1.03 (0.96 to 1.11)
<5 years exposure
12 22 24 25 1.10 (0.97 to 1.23)
>5 years exposure
11 23 26e28 1.06 (0.97 to 1.17)
<5 years follow-up
22 24 25 0.95 (0.78 to 1.17)
>5 years follow-up
11 12 23 26e28 1.09 (1.00 to 1.18)
Folic acid given in combination
with other B vitamins
12 24e28
1.06 (0.99 to 1.13)
Folic acid given with aspirin
11 22 1.43 (1.00 to 2.03)
Folic acid given in countries
with fortiﬁcation
24 26
0.95 (0.81 to 1.13)
Figure 3 Forest plot of randomised controlled trials that compare folic acid supplements $0.4 g/day with placebo/control
treatment with respect to prostate cancer incidence.
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Cancer risk with folic acid supplementsAll meta-analyses of mortality of site-speciﬁc cancers
had results that were not statistically signiﬁcant in RCTs
(data available at the web pages of the Norwegian
Knowledge Centre for the Health Services
18). None of
the observational studies addressed mortality.
DISCUSSION
In the present systematic review, a meta-analysis of 10
RCTs showed a borderline signiﬁcant incidence increase
of overall cancer in the folic acid group compared to
controls. Overall cancer incidence was not reported in
the seven observational studies. However, meta-analysis
of the seven observational studies including all cancer
types reported showed no difference in cancer incidence
between the group taking folic acid supplements and
abstainers.
In sensitivity analyses, we identiﬁed four subgroups
where folic acid supplementation increased cancer
incidence and/or cancer mortality. These subgroups
consisted of studies with a dose of folic acid from 0.4 mg
to 1 mg/day, studies with >30% of smokers, studies with
>70% of men and studies with a follow-up longer than
5 years. Whether smoking, gender, follow-up time or any
other unreported reasons are the factors that contribute
to this adverse effect of folic acid has not been studied.
Comparison with other studies
Our ﬁnding of no beneﬁt, but a possible adverse effect
from folic acid supplementation on cancer incidence is
in line with reported results of studies on other nutrient
supplements, including vitamin E, b-carotene (vitamin-A
precursor) or selenium; all showing no or an adverse
effect of supplementation in controlled clinical trials on
cancer development.
42 43 A recent meta-analysis of folic
acid supplements by Clarke and coworkers, in the
‘B-Vitamin Treatment Trialists’ Collaboration’
3 with
individual patient data, found no increased cancer risk in
any subgroups. Our analysis differs from Clarke’s by
being a systematic review, thus including more studies
(ﬁve more RCTs and seven observational studies) and
by including more diverse populations than the seven
B-vitamin trials in populations with cardiovascular disease
included in the Clarke’s study. In two studies included
both in Clarke’s meta-analysis and in ours, NORVIT and
WENBIT, we included data from the combined analysis
with longer follow-up time published in 2009
12; whereas
Clarke et al only use cancer data from the original
papers
13 14 with a shorter follow-up. When assessing
possible harm, a longer follow-up time is beneﬁcial in
order to discover more potential cancer cases, as an
augmented cancer risk after folic acid intervention may
not be conﬁned to a short post-trial time period.
In our sensitivity analyses of the RCTs, the studies with
the largest proportions of smokers showed an increased
risk of cancer incidence and cancer mortality associated
with folic acid supplements. Smoking is a well-known risk
factor for many cancers. Furthermore, unlike folate
supplements, folate from diet seems to be protective for
cancer development.
7 Many smokers have poor dietary
habits, and folate intake has been shown to be inversely
associated with smoking duration.
44 Recently, the Euro-
pean Prospective Investigation into Cancer and Nutri-
tion, a large observational study, found a lower risk of
developing lung cancer in former and current smokers
within the highest quartile of serum folate compared to
the lowest (OR 0.68, 95% CI 0.51 to 0.90).
45 No effect
was apparent in never-smokers (OR 0.84, 95% CI 0.43 to
1.65) or for colorectal cancer risk.
46 Interestingly, and in
line with a possible adverse effect of folic acid supple-
mentation, another report from the European Prospec-
tive Investigation into Cancer and Nutrition study
suggests a U-shaped relationship between plasma folate
and risk of pancreatic cancer in both men and women,
with highest risk for the lowest and highest serum
quintile levels.
47
A large Swedish prospective study found that pancre-
atic cancer risk was reduced in people with diets rich in
folate from foods but not from supplements.
48 This is in
line with other observational studies indicating a source-
speciﬁc effect of folates with dietary folate being
protective and folic acid supplements possibly being
harmful or having no effect with respect to cancer
risk.
49e52 In one of the RCTs included in our analysis,
41
folic acid supplementation of 1 mg/day increased the
risk of prostate cancer, while higher dietary folate and
plasma folate levels among non-users of vitamin
supplements were associated with decreased risk of
prostate cancer.
53
Figure 4 Forest plot of randomised controlled trials that compare folic acid supplements $0.4 g/day with placebo/control
treatment with respect to total cancer mortality.
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Cancer risk with folic acid supplementsIt has been speculated that folate may be beneﬁcial in
primary prevention of cancer, but potentially harmful in
the presence of early cancer.
10 Accordingly, the anti-
folate methotrexate is an effective cytostatic drug used in
the standard therapy of several cancer types. We
performed sensitivity analyses for the folic acid supple-
mented population with a history of adenomas and the
populations without such a history. This analysis showed
no signiﬁcant increased risk of colorectal cancer in
either group. It should be noted, however, that we do not
have data to support or weaken the interesting hypoth-
esis of timing of folate supplementation as being
important. The relative short latency time from exposure
(folate supplementation) to cancer development
reported from the recent Norwegian randomised trials
12
suggests an effect on late carcinogenesis, as this short
time indicates that a precancer situation might have
been present during the intervention period.
In our sensitivity analyses of the RCTs, the studies with
dose interval 0.4e1 mg/day were associated with
a higher risk of cancer development than studies with
doses above 1 mg/day, with RRs of 1.21 (95% CI 1.06 to
1.38) and 1.03 (95% CI 0.96 to 1.11), respectively. Our
systematic search had no dose limitation and thus
allowed us to search for all dose ranges, although our
eligibility criteria speciﬁed doses $0.4 mg/day. We
identiﬁed no RCTs, but 11 observational studies with
doses below 0.4 mg/day reporting cancer incidence,
thus allowing us post hoc to evaluate a possible
doseeresponse pattern of observational studies
including doses below 0.4 mg/day. Six of these studies
were already included in our review, as they also
contained groups with daily intakes $0.4 mg,
32e34 36e38
and ﬁve were excluded from our main analyses due to
daily dose of folic acid below 0.4 mg.
49 50 54e56 No
increased risk was found in the meta-analyses of doses
below 0.4 mg/day, with RR of 1.07 (95% CI 0.92 to 1.26)
for the cohort studies
33 34 36e38 49 50 54 56 and 1.17 (95%
CI 0.58 to 2.33) for the caseecontrol studies.
32 55 Hence,
our analyses did not indicate any doseeresponse pattern
between folic acid dose and cancer incidence.
The reason for the increased risk in the dose interval
0.4e1 mg/day has not been elucidated in our study, and
we cannot exclude that other characteristics of these
particular studies may be confounders. Although the
smokers are randomised and evenly distributed between
folic acid and placebo groups, one might speculate that
a possible harmful effect of folic acid on smokers will be
more evident in studies with more smokers.
A high alcohol intake is associated with higher inci-
dence of several cancer types, including premenopausal
and postmenopausal breast cancer.
7 Folate intake or
blood folate do not seem to inﬂuence breast cancer risk,
but adequate folate may reduce the increased risk asso-
ciated with alcohol consumption.
57 A similar association
between alcohol consumption and folate intake is
reported in a prospective cohort study from the Nurses’
Health Study on oral cancer risk in women.
58 The effect
of alcohol consumption on cancer development after
folic acid supplementation was not possible to evaluate
in the present study, due to restricted information in the
original publications on alcohol intake.
When different cancer sites were assessed in our study,
prostate cancer was the only cancer type found in the
pooled analysis to have a signiﬁcant risk increase after
folic acid supplementation. There was some heteroge-
neity between the studies (I
2¼17%), with one of the
trials, AFPPS
41 being an outlier compared to the other
studies with an RR of 2.68 (95% CI 1.27 to 5.66).
However, the increased risk remained even if omitting
this study from the pooled effect estimate (RR 1.19, 95%
CI 1.01 to 1.39, I
2¼0%). In line with our results, a recent
meta-analysis on serum folate and prostate cancer
59
concluded that high serum folate concentrations were
associated with increased prostate cancer risk. We may
speculate on a speciﬁc effect of folic acid on prostate
tissue rather than on cancer development in general due
to differences in tissue and cell sensitivity to folic acid
effects. Such potential tissue- and cell-speciﬁc differ-
ences in folic acid effects on cell biology need to be
further explored in order to generate a molecular
understanding for such a possible diverse tissue effect.
The major group recommended taking folic acid
supplements today is women in childbearing age before
and in the ﬁrst trimester of pregnancy in order to prevent
neural tube defects in the offspring. Only one of the
studies in our review was performed in a population of
pregnant women, the 36-year post-trial follow-up after an
RCT in Scottish women taking folic acid in pregnancy.
29
This study of Charles et al showed a signiﬁcant increased
risk for total cancer mortality (RR 1.70, 95% CI 1.06 to
2.72) in pregnant women with folic acid supplementa-
tion, in the group taking the highest dosage of folic acid,
5 mg/day, but not in the 0.2 mg group (RR 1.20, 95% CI
0.71 to 2.02). However, in our meta-analysis of total cancer
mortality, where the study of Charles et al was analysed
together with ﬁve other studies, no signiﬁcant increase in
total mortality was showed (RR 1.09, 95% CI 0.92 to 1.30).
The 5 mg daily dose far exceeds the folic acid supple-
mentation dosage recommended today for the female
fertile population (0.4 mg/day). It is worth noticing also
that the proportion of smokers in the study of Charles
et al was high (>40%), which reﬂects smoking habits in
the 1960s when the study was performed. Another study
assessing cancer effects after folic acid supplements in
pregnancy showed a reduced risk of childhood leukaemia
(acute lymphoblastic leukaemia) in the offsprings.
60 This
study was, however, not included in our present analysis,
as folic acid supplement dose was not speciﬁed.
The folic acid recommendations in order to reduce
risk of fetal neural tube development are poorly followed
by fertile women, as few women start folic acid intake
prior to pregnancy.
61 62 Several countries, such as
Canada and the USA, have started fortiﬁcation of foods
in order to increase periconceptional folic acid intake,
aiming at reducing the incidence of neural tube defects.
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Cancer risk with folic acid supplementsThis food fortiﬁcation strategy has been shown to efﬁ-
ciently reduce the incidence of open neural tube defects
in Canada.
63 Other countries, such as Norway
64 and the
UK, have not chosen this general food fortiﬁcation
strategy, mainly due to the unknown effects of
augmented folic acid intake on the general population
outside the target group of fertile women, such as
masking of vitamin B12 deﬁciency in the older popula-
tion and a possible risk of cancer development. Longi-
tudinal studies on cancer development in countries that
have introduced fortiﬁcation of foods with folic acid
could indicate whether fortiﬁcation has similar risk of
cancer as what seems to be the case for folic acid
supplements. At present, there are no studies indicating
that the current recommendation of folic acid supple-
mentation (with the present recommended moderate
dosages) to fertile women has any negative effects on the
woman’s or the offspring’s future health.
Folic acid may alternatively be administered as 5-
methyltetrahydrofolate, as in the SU-FOL.OM3-trial,
65
where patients in France with a history of ischaemic
heart disease were randomised to either receive B vita-
mins (5-methyltetrahydrofolate, vitamin B6 and vitamin
B12 or placebo) and u-3 fatty acids or placebo in a 232
factorial design. Mean duration of supplementation and
of follow-up was 4.7 years. In this study, allocation to
B-vitamins did not have any signiﬁcant effect on cancer
incidence (HR 1.19, 95% CI 0.88 to 1.60). Adding this
study to our meta-analysis of total cancer incidence
would, however, not change the conclusions, with
a pooled effect estimate (RR 1.08, 95% CI 1.01 to 1.14).
Strengths and limitations of the study
Our review has several strengths. Our thorough system-
atic search makes it plausible that we have retrieved all
relevant studies and can be assured not to miss impor-
tant data. However, not all studies could be included in
our meta-analyses due to unreported outcomes or dose
of folic acid in supplements. The data extraction has
been performed by individual reviewers and then
controlled by others, which also strengthens our trust in
this review. Additionally, most of the RCTs included are
of high methodological quality, with a low risk of bias.
This generally implies that we can be quite conﬁdent
that the different study groups were randomised
adequately and that the result from the studies can be
trusted. Also, in some of the included studies, cancer
cases found shortly after initiation of the study were
excluded since it would be biologically implausible that
these cases were related to the intervention.
The limited time of follow-up of most RCTs is a major
limitation of our review because the time frame for
cancer development might exceed the follow-up time in
many RCTs. Actually, this review may be too conservative
regarding estimating the long-term cancer risk associ-
ated with folic acid supplementation since regularly
RCTs have a short follow-up time. This is also supported
by our sensitivity analysis where the subgroup of studies
with the longer follow-up time showed borderline
increase in cancer risk with folic acid supplements,
whereas the studies with shorter follow-up did not.
However, when we add observational studies to broaden
the evidence base and lengthen follow-up time, we do
not ﬁnd any additional risk difference between the
groups.
Another limitation of our study is the lack of infor-
mation on dietary patterns in the studied populations as
the effect of supplements may vary according to the
folate status of the population, for example, the
proportion that are folate deﬁcient. However, this is not
thought to vary within one single study (RCTs) but may
vary between studies and countries. In one of the RCTs,
11
baseline dietary data were supplied in a separate paper,
53
and although it showed an inverse association between
high dietary intake and colorectal adenoma in the
placebo group, thus indicating a protective effect, no
association between dietary folate and colorectal
adenoma was shown in the folic acid-supplemented
group. The authors interpreted this as a beneﬁcial effect
of folate supplementation compared to deﬁciency but
limited to some point of sufﬁciency, where increases
provide no additional beneﬁt. Our analysis may
emphasise the need for pooling all relevant evidence
into meta-analyses when appropriate and not trying to
interpret conﬂicting results only based on one single
RCT.
Another important limitation of our review is the
selected populations in which the RCTs were performed,
thus the ﬁndings may not be applicable to the popula-
tion in general. Most participants included were treated
in secondary prevention of adenomas and cardiovascular
disease and may have increased cancer risk, for example,
smoking is a common risk factor for cancer and
cardiovascular disease. The one study with pregnant
women had a higher proportion of smokers than is
reported today.
66 Effects of folic acid supplementation
may vary among different subgroups, as demonstrated
on trial level in our analysis. Our conclusions are
based on RCTs with a low risk of bias, and randomisation
of participants should minimise the problem of
confounding.
We performed only regular meta-analyses and analysed
sensitivity by dividing the results into groups. A more
sophisticated way of investigating impact of different
possible factors is to perform meta-regression.
19
However, this is not recommended if <10 studies are
included.
19 Furthermore, we could not perform sensi-
tivity analyses on some other variables that would be of
interest, for instance on shorter periods of folic acid
exposure that is more common in pregnancy.
More studies assessing cancer risk in the only popula-
tion where folic acid supplementation is shown to be
beneﬁcial today (periconceptionally to fertile women to
prevent neural tube defects) would have strengthened
the analysis. However, the one long-term follow-up
after such folic acid supplementation
29 did not ﬁnd an
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Cancer risk with folic acid supplementselevated mortality rate for any cancer (total cancers and
breast cancer analysed separately) following the low
supplementation dosage of 0.2 mg daily.
Our review has not addressed dietary folate, and we
cannot conclude on a possible ‘source-speciﬁc’ effect. A
Cochrane review under preparation is addressing this
issue.
67
Conclusions and policy implications
A meta-analysis of 10 RCTs showed a borderline signiﬁ-
cant increase in incidence of overall cancer in the folic
acid group compared to controls. Overall cancer inci-
dence was not reported in the seven observational
studies. Longer follow-up than in ordinary RCTs might
be needed to conﬁrm this ﬁnding of a possible border-
line signiﬁcant increase in overall cancer incidence in
the folic acid group compared to controls. Our analysis
identiﬁed a very moderate, although statistically signiﬁ-
cant, elevated risk of prostate cancer after folic acid
supplementation. A major limitation of our study is the
highly selected population in which most of the studies
were conducted (to prevent clinical events in heart
disease patients), and the ﬁndings might not be appli-
cable to the major groups currently recommended to
take folic acid supplements, that is, women of child-
bearing age. Longitudinal studies on cancer develop-
ment in countries that have introduced fortiﬁcation of
foods with folic acid, such as in the USA and Canada,
could indicate whether fortiﬁcation similar to supple-
mentation moderately increases prostate cancer risk
simultaneously with the positive effect of reducing
neural tube defects.
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